



New Pharma

Protocol: 2011-01 Investigator Number: 021 Subject: LAT/1001

## Concomitant Medications

### End of Study

- End of Study Page

### • Concomitant Medications

- Adverse Events

#	Medication	Dose	Unit	Route	Frequency	Start Date	Stop Date	Continuing?	Indication
1	Fexofenadine HCL	180	Mg	PO	QD	—/Mar/2011		Yes	Allergic Rhinitis
2	Enalapril Maleate	5	Mg	PO	BID	—/—/2013		Yes	Hypertension
3	Ertiegli-flozin/ Sitagliptin	5/100	Mg	PO	QD	—/Jan/2016		Yes	Diabetes Mellitus Type II
4	Paracetamol	1000	Mg	PO	BID	—/Jul/2016		Yes	Osteoarthritis— Right Hip
5	Famotidine	20	Mg	PO	QD	—/Jan/2015		Yes	Gastroesophageal Reflux Disease
6	Hydrochlorothiazide	25	Mg	PO	QD	—/Mar/2018		Yes	Lower Extremity Edema
7	Budesonide	180	Mcg	INH	BID	—/May/2018		Yes	Asthma
8	Albuterol	90	Mcg	INH	PRN	—/May/2018		Yes	Asthma
9	Diltiazem	300	Mg	PO	QD	—/May/2018		Yes	Atrial Fibrillation
10	Aflibercept	.05	MI	IVA	Q2M	—/Dec/2018		Yes	Diabetic Retinopathy
11	Escitalopram	10	Mg	PO	QD	—/Mar/2020		Yes	Depression